Real-time enrollment status for this exocrine pancreatic insufficiency (epi) clinical trial
Current Status
Recruiting
Checked: October 1, 2026 at 9:51 PM UTC
| NCT Number | NCT07559175 |
| Recruiting Status | Recruiting |
| Condition | Exocrine Pancreatic Insufficiency (EPI) |
| Phase | PHASE2 |
| Target Enrollment | 66 participants |
| Active Locations | 14 sites in the US |
| Sponsor | Aimmune Nestlé Health Science US R&D, LLC |
| Last Updated on CT.gov | October 1, 2026 (21 hours ago) |
As of October 1, 2026: Clinical trial NCT07559175 is currently recruiting participants. This phase2 study for exocrine pancreatic insufficiency (epi) is actively seeking new participants at 14 locations across the United States. The study is sponsored by Aimmune Nestlé Health Science US R&D, LLC. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07559175 is actively recruiting participants as of October 1, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 14 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07559175 was last updated 21 hours ago (October 1, 2026). HelloStudys verifies this status automatically.